The value of a healthtech startup cannot be judged by revenue alone, because in this sector growth, clinical validation, regulatory progress and strategic positioning often matter as much as turnover. Unlike more traditional businesses, healthtech companies may spend years building technology, collecting evidence, securing approvals and integrating with healthcare systems before generating significant sales.

This means investors and founders must look beyond short-term financial performance to assess a company’s real worth. Key indicators can include the strength of the product, the quality of the medical or scientific validation, the size of the addressable market, the level of adoption by healthcare professionals or institutions, and the startup’s ability to navigate complex regulatory and reimbursement environments.

In healthtech, a startup with modest revenue may still have substantial value if it has developed a differentiated solution, built strong intellectual property, or established partnerships that position it for scale. Conversely, a company with higher turnover may be less valuable if its growth is fragile, its margins are weak, or its product lacks long-term defensibility.

For this reason, valuation in healthtech is typically more nuanced than in other sectors: it reflects not just current sales, but also the potential to transform care delivery, improve outcomes and create durable competitive advantages in a highly regulated market.

L’article Healthtech : pourquoi la valeur d’une start-up ne se mesure pas uniquement à son chiffre d’affaires est apparu en premier sur Maddyness - Le média pour comprendre l'économie de demain.